Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Current Deferred Revenue (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Current Deferred Revenue for 3 consecutive years, with $23683.0 as the latest value for Q3 2022.

  • Quarterly Current Deferred Revenue changed N/A to $23683.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $23683.0 through Sep 2022, changed N/A year-over-year, with the annual reading at $2.3 million for FY2020, N/A changed from the prior year.
  • Current Deferred Revenue for Q3 2022 was $23683.0 at Inhibikase Therapeutics, roughly flat from $23684.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $2.3 million in Q4 2020, with the low at $23683.0 in Q3 2022.
  • Average Current Deferred Revenue over 3 years is $753415.2, with a median of $142619.0 recorded in 2021.
  • Peak annual rise in Current Deferred Revenue hit 83.39% in 2022, while the deepest fall reached 83.39% in 2022.
  • Over 3 years, Current Deferred Revenue stood at $2.3 million in 2020, then crashed by 93.87% to $142619.0 in 2021, then tumbled by 83.39% to $23683.0 in 2022.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $23683.0, $23684.0, and $142619.0 for Q3 2022, Q2 2022, and Q2 2021 respectively.